Drug Profile
Mevociclib - Syros Pharmaceuticals
Alternative Names: SY-1365Latest Information Update: 03 Apr 2023
Price :
$50
*
At a glance
- Originator Syros Pharmaceuticals
- Class Amides; Amines; Antineoplastics; Chlorinated hydrocarbons; Cyclohexanes; Indoles; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Haematological malignancies; Ovarian cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 31 Dec 2022 Syros pharmaceuticals has patent protection in USA
- 23 Oct 2019 Discontinued - Preclinical for Haematological malignancies and Acute myeloid leukaemia in the USA (Parenteral); Phase-I for Solid tumours, Ovarian cancer and Breast cancer in the USA (IV) because data obtained did not support an optimal profile for patients and indicated higher or frequent dosing
- 07 Dec 2018 Pharmacodynamics data from preclinical trials in Breast cancer presented at the 41st Annual San Antonio Breast Cancer Symposium (SABCS-2018)